Navigation Links
Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy
Date:3/30/2015

GERMANTOWN, Md., March 30, 2015  /PRNewswire/ -- Intrexon Corporation (NYSE: XON), a leader in synthetic biology, and Merck Serono, the biopharmaceutical business of Merck KGaA, Darmstadt, Germany, today announced an exclusive strategic collaboration and license agreement to develop and commercialize Chimeric Antigen Receptor T-cell (CAR-T) cancer therapies. This collaboration advances Merck Serono's comprehensive, science-driven strategy to develop innovative therapies that modulate the immune system's natural ability to fight tumors.

"The collaboration with Intrexon underlies Merck Serono's focus on innovation, and enhances its R&D technology portfolio in immuno-oncology," says Belen Garijo, President and CEO of Merck Serono. "Moreover, it showcases Merck Serono's commitment to developing therapies that have the potential to significantly evolve the way cancer is treated."

CAR-T cells are genetically engineered T-cells with synthetic receptors that recognize a specific antigen expressed on tumor cells. When CAR-T cells bind to a target, an immunological attack against the cancer cells is triggered. 

Utilizing Intrexon's cell engineering techniques and RheoSwitch® platform, the collaboration aims to develop leading-edge products that empower the immune system in a regulated manner to overcome the current challenges of CAR-T therapy. 

The agreement provides Merck Serono exclusive access to Intrexon's proprietary and complementary suite of technologies to engineer T-cells with optimized and inducible gene expression, as recently strengthened by a license agreement with the University of Texas MD Anderson Cancer Center.

Intrexon will be responsible for all platform and product developments until IND filing. Merck will nominate targets of interest for which CAR-T products will be developed. Merck will also lead the IND filing and pre-IND interactions, clinical development and commercialization. In addition, Intrexon has the opportunity to explore targets independently, granting Merck opt-in rights during clinical development.

"Merck is an ideal partner in CAR-T for us because of their long-term perspective, extraordinary character, worldwide reach and commitment to leadership in immuno-oncology," says Randal J. Kirk, Chairman and CEO of Intrexon.  "We look forward to working together to benefit patients through the creation of a leading franchise in this very promising field."

Under the terms of the agreement, Intrexon will receive an upfront payment of $115 million. For the first two targets of interest selected by Merck Serono, Intrexon will receive research funding and is eligible to receive up to $826 million development, regulatory and commercial milestones, as well as tiered royalties on product sales.  In addition, Intrexon is also eligible to receive further payments upon achievement of certain technology development milestones.

About Merck Serono

Merck Serono is the biopharmaceutical business of Merck. With headquarters in Darmstadt, Germany, Merck Serono offers leading brands in 150 countries to help patients with cancer, multiple sclerosis, infertility, endocrine and metabolic disorders as well as cardiovascular diseases. In the United States and Canada, EMD Serono operates as a separately incorporated subsidiary of Merck Serono.

Merck Serono discovers, develops, manufactures and markets prescription medicines of both chemical and biological origin in specialist indications. We have an enduring commitment to deliver novel therapies in our core focus areas of neurology, oncology, immuno-oncology and immunology.

For more information, please visit www.merckserono.com

About Intrexon Corporation

Intrexon Corporation (NYSE: XON) is a leader in synthetic biology focused on collaborating with companies in Health, Food, Energy, Environment, and Consumer sectors to create biologically-based products that improve the quality of life and the health of the planet.  Through the Company's proprietary UltraVector® platform and integrated technology suite, Intrexon provides its partners with industrial-scale design and development of complex biological systems delivering unprecedented control, quality, function, and performance of living cells.  We call our synthetic biology approach Better DNA®, and we invite you to discover more at www.dna.com.

Trademarks

Intrexon, RheoSwitch, RheoSwitch Therapeutic System, RTS, UltraVector, and Better DNA are trademarks of Intrexon and/or its affiliates.  Other names may be trademarks of their respective owners.

Safe Harbor Statement

Some of the statements made in this press release are forward-looking statements.  These forward-looking statements are based upon our current expectations and projections about future events and generally relate to our plans, objectives and expectations for the development of our business.  Although management believes that the plans and objectives reflected in or suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties and actual future results may be materially different from the plans, objectives and expectations expressed in this press release.

For more information regarding Intrexon Corporation, contact:

Investor Contact:
Christopher Basta
Vice President, Investor Relations
Tel: +1 (561) 410-7052
Investors@intrexon.com

Corporate Contact:
Marie Rossi, Ph.D.
Senior Manager, Technical Communications
Tel: +1 (301) 556-9850
publicrelations@intrexon.com

Logo - http://photos.prnewswire.com/prnh/20130919/NY83283LOGO


'/>"/>
SOURCE Intrexon Corporation
Copyright©2015 PR Newswire.
All rights reserved

Related biology technology :

1. Synthetic Biologics Reiterates that the Infectious Disease Collaboration with Intrexon Remains in Effect
2. Intrexon Corporation Raises $150 Million for Synthetic Biology Initiatives
3. Intrexon Organizes Around New Synthetic Biology Markets
4. Intrexon Announces Filing of Registration Statement For Proposed Initial Public Offering
5. Intrexon Prices Initial Public Offering
6. Intrexon Announces Closing of Initial Public Offering and Full Exercise of Over-Allotment Option by Underwriters
7. Intrexon and Rentokil Enter into Research and Development Agreement to Explore a New Generation of Highly-Effective, Sustainable Pest Controls
8. Intrexon Establishes "Living Arts" Company, BioPop, to Create Consumer Products Inspired by Nature and Made Possible through Science
9. Intrexon Strengthens Leadership in Companys Rapidly Growing Health Sector
10. Agilis Biotherapeutics and Intrexon to Pursue Transformative Therapies for Rare Genetic Disease
11. Fibrocell Science and Intrexon Expand Collaboration to Include Hypermobility-Type Ehlers-Danlos Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/3/2019)... ... 2019 , ... Cheyenne is a beautiful and strong Quarter Horse and a ... Rebel’s Run , which offers riding lessons and trail riding in Afton, Virginia. ... Mimi describes her as her “go to horse.” Thus, you can imagine ...
(Date:10/3/2019)... (PRWEB) , ... October 03, 2019 , ... Yesterday, at ... Asymmetrex founder and director, James L. Sherley, M.D., Ph.D., discussed important design ... To an attendee audience including both developers and suppliers of clinical trials, in his ...
(Date:9/24/2019)... ... September 24, 2019 , ... ... company, has completed training and site qualification for clinical trial sites and physician ... and screening of potential clinical trial participants. , Clinical trial sites are currently ...
(Date:9/17/2019)... ... September 17, 2019 , ... Tucker, a Labrador retriever, was ... months old, Tucker was limping and lame on his right hip and elbow. At ... it was called “the worst case the vet had seen.” He was prescribed pain ...
Breaking Biology Technology:
(Date:10/3/2019)... ... ... Personalized Stem Cells, Inc (“PSC”), a human adipose-derived stem cell company, ... stem cell treatment of knee osteoarthritis . The successful enrollment comes only a little ... Biopharma. , PSC CEO, Michael Dale, stated, “We are proud that as we celebrate ...
(Date:9/30/2019)... ALTO, Calif. (PRWEB) , ... September 30, 2019 ... ... public interest organization focused on molecular manufacturing and other transformative technologies, announced the ... categories, one for Experiment and the other for Theory in nanotechnology/molecular manufacturing. , ...
(Date:9/30/2019)... ... September 30, 2019 , ... As human induced pluripotent stem cells (hiPSCs) ... the development and diseases of the human heart, there is an increasing need for ... muscle cells to be clearly and easily recorded. A study released today in STEM ...
Breaking Biology News(10 mins):